This antimicrobial resistance surveillance study was performed in 100 medical centers. Susceptibility testing (Etest; AB BIODISK, Solna, Sweden) of 9152 strains including @entity526 (991 strains), @entity4005 spp. (1000 strains), Enterobacter spp. (971 strains), Citrobacter spp. (803 strains), @entity104 -positive Proteae spp. (834 strains), Serratia spp. (902 strains), Acinetobacter spp. (874 strains), @entity796 (992 strains), @entity6101 -susceptible @entity794 (984 strains), and coagulase-negative staphylococci (CoNS; 801 strains) was performed with 7 @entity7660 ( @entity6944 , cefpirome, @entity5505 , @entity2891 / @entity5899 , @entity2892 and @entity3400 for Gram-negative bacteria, or @entity6101 for Gram-positive bacteria). No strain resistance to these @entity7660 (except for @entity5505 ) was found in @entity6101 -susceptible @entity794 and CoNS. Of the @entity526 clinical isolates, 17.1% were resistant to @entity3400 , whereas 2.9% or less (cefpirome = 2.9%) were resistant to other @entity3405 agents. @entity4005 spp. strains were more susceptible to @entity2892 (99.9%), @entity6944 (99.2%), @entity5505 (98.6%), and cefpirome (98.3%). Isolates of Enterobacter spp., Citrobacter spp., @entity104 -positive Proteae, and Serratia spp. were susceptible to @entity2892 , @entity6944 , and cefpirome as well. Acinetobacter spp. strains were least resistant to @entity2891 / @entity5899 (0.7% resistance), @entity2892 (2.6%), @entity6944 (6.6%), and @entity5505 (7.7%) compared with other @entity3405 antibiotics tested. Isolates of @entity796 were more susceptible to @entity5505 (8.7% resistance), @entity2891 / @entity5899 (9.8%), and @entity6944 (8.9%) than @entity3400 (11.9%), cefpirome (16.2%), and @entity2892 (12.4%). The percentage of @entity2892 -resistant @entity796 was approximately 13% in clinical isolates in Japan. The proportion of strains resistant to @entity3405 antimicrobials has been decreasing compared with data from 2004, suggesting that reduced consumption of @entity7660 has reflected the decreased rates of resistant bacterial isolates in Japan.

Evaluation of antimicrobial susceptibility for XXXX using the Etest method against clinical isolates from 100 medical centers in Japan (2006).

@entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem'] @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa', 'P. aeruginosa'] @entity3405 :: ('CHEBI:35627', 'Chemical') :: ['beta-lactam'] @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli'] @entity6944 :: ('MESH:C043266', 'Chemical') :: ['cefepime'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus'] @entity7660 :: ('MESH:D047090', 'Chemical') :: ['beta-lactams'] @entity6101 :: ('MESH:D010068', 'Chemical') :: ['oxacillin'] @entity4005 :: ('MESH:D007710', 'Disease') :: ['Klebsiella'] @entity3400 :: ('MESH:D010878', 'Chemical') :: ['piperacillin'] @entity2891 :: ('MESH:D002438', 'Chemical') :: ['cefoperazone'] @entity5899 :: ('MESH:D013407', 'Chemical') :: ['sulbactam'] @entity5505 :: ('MESH:D002442', 'Chemical') :: ['ceftazidime'] @entity104 :: ('MESH:C030374', 'Chemical') :: ['indole']
@entity7660 :: (MESH:D047090,Chemical) :: ['beta-lactams']
